People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elion Therapeutics, Inc. | — | Biotechnology | Series B | $25.4M | $185.8M | 2024 |
| Pearl Diagnostics, Inc. | — | Biotechnology | Seed | $3.5M | $62.9M | 2022 |
Kieren Marr at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kieren Marr on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Leff | 1 | 11 |
| Martin Heidecker | 1 | 6 |
| Jim Flynn | 1 | 4 |
| John Cammack | 1 | 3 |
| Brad Spellberg | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.